Company Filing History:
Years Active: 2010
Title: Mette Munch: Innovator in TNF Antagonists
Introduction
Mette Munch is a prominent inventor based in Egå, Denmark. She has made significant contributions to the field of biotechnology, particularly in the development of TNF antagonists. Her work focuses on creating polypeptides that have improved binding characteristics and efficacy for therapeutic applications.
Latest Patents
Mette Munch holds a patent for "TNF antagonists - TNF binding polypeptides based on human tetranectin C-type lectin like domains (CTLD) with improved binding characteristics and improved efficacy." This innovative patent includes polypeptides that comprise a TNF binding domain with the amino acid sequence KRWS-RYF (SEQ ID NO:1). The polypeptides can be utilized in the preparation of pharmaceutical compositions and for treating conditions mediated by TNF, such as rheumatoid arthritis. She has 1 patent to her name.
Career Highlights
Mette Munch is associated with Anaphore, Inc., where she continues to advance her research and development efforts. Her work has the potential to impact the treatment of various pathologies, showcasing her dedication to improving patient outcomes through innovative solutions.
Collaborations
Mette collaborates with notable colleagues, including Helle Krogh Ottow and Thor Las Holtet. Their combined expertise enhances the research environment and fosters innovation within their projects.
Conclusion
Mette Munch is a trailblazer in the field of biotechnology, particularly in the development of TNF antagonists. Her innovative work and collaborations position her as a key figure in advancing therapeutic solutions for patients.